<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881306</url>
  </required_header>
  <id_info>
    <org_study_id>NET11330</org_study_id>
    <nct_id>NCT03881306</nct_id>
  </id_info>
  <brief_title>DEBOXA for Inoperable NET Liver Metastases</brief_title>
  <official_title>CalliSpheres Drug-Eluting Beads With Oxaliplatin to Treat Inoperable NET Liver Metastases: A Multi-center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective clinical trial to study the safety and effectiveness of Transcatheter Artery&#xD;
      Chemotherapy and Embolization (TACE) using CalliSpheres Drug-Eluting Beads with oxaliplatin&#xD;
      (DEBOXA) in treating patients who have inoperable neuroendocrine neoplasm (NEN) liver&#xD;
      metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety and effectiveness of Transcatheter Artery Chemotherapy and&#xD;
      Embolization (TACE) using CalliSpheres Drug-Eluting Beads with oxaliplatin (DEBOXA) in&#xD;
      patients with inoperable neuroendocrine neoplasm (NEN) liver metastases.&#xD;
&#xD;
      II. Determine the response rate (RR) of intrahepatic lesions in patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      III. Determine the overall survival (OS), progression-free survival time (DFS), time to&#xD;
      hepatic progression (THP), and quality of life (QOL) in patients treated with this regimen.&#xD;
&#xD;
      IV. Safety assessment: adverse events (AEs) and severe adverse events(SAEs)&#xD;
&#xD;
      OUTLINE: This is a single-arm, multi-center, prospective study.&#xD;
&#xD;
      Patients receive D-TACE. Embolization agent: CalliSpheres Drug-Eluting Beads. Chemotherapy&#xD;
      agent: oxaliplatin. Treatment repeats every 5 weeks in the absence of progression of hepatic&#xD;
      lesions, or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR) of intrahepatic lesions</measure>
    <time_frame>2 years</time_frame>
    <description>Assess the Disease control rate (DCR) of intrahepatic lesions by enhanced CT or MRI scan according to RECIST criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>30 month</time_frame>
    <description>From the date of first D-TACE to the date of death from any cause or to completion of trial, whichever comes first, up to 30 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>30 months</time_frame>
    <description>From the date of first D-TACE to the date of documented disease progression, including progression of intrahepatic lesions and progression of extrahepatic lesions, or to completion of trial, whichever comes first, up to 30 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QOL)</measure>
    <time_frame>30 months</time_frame>
    <description>Assessed according to EORTC QLQ-C30(V3.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects and adverse events</measure>
    <time_frame>30 months</time_frame>
    <description>To determine the safety and tolerability of DEBOXA for NEN liver metastases</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <condition>Neoplasm Metastasis</condition>
  <condition>Liver</condition>
  <arm_group>
    <arm_group_label>D-TACE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-TACE for inoperable NEN liver metastases. Embolization agent: CalliSpheres Drug-Eluting Beads Chemotherapy agent: Oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-TACE</intervention_name>
    <description>D-TACE with CalliSpheres-Oxaliplatin</description>
    <arm_group_label>D-TACE</arm_group_label>
    <other_name>CalliSpheres-Oxaliplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis is confirmed by biopsy or clinical data, primary site is resected or primary&#xD;
             site is not resected but without risks of bleeding, obstruction in the near future.&#xD;
&#xD;
          -  Failure of ≥ 1 system treatment, such as long-acting somatostatin or EP chemotherapy&#xD;
             regimen.&#xD;
&#xD;
          -  Standard surgical resection can not be performed because of extent liver involvement&#xD;
             （liver involvement ≥ 2 lobes or ≥ 2 major vessels）, or patients who are not willing to&#xD;
             accept surgical operation.&#xD;
&#xD;
          -  Predicted survival &gt;3 months.&#xD;
&#xD;
          -  Child Pugh Score: ≤ 7&#xD;
&#xD;
          -  ECOG score for performance status: 0-1&#xD;
&#xD;
          -  Informed consensus is achieved.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastases to other organs or sites besides liver.&#xD;
&#xD;
          -  Prior TACE for liver tumors in 1 year.&#xD;
&#xD;
          -  Obvious hepatic arterio-venous shunt or arterio-portal shunt.&#xD;
&#xD;
          -  Prior or concurrent malignancy (Except basal carcinoma or squamous carcinoma of skin&#xD;
             or carcinoma in situ of cervex uteri which has been cured).&#xD;
&#xD;
          -  Platelet count &lt; 50,000/mm^3 or white blood cell count &lt;3,000 /mm^3 without&#xD;
             hypersplenism.&#xD;
&#xD;
          -  Creatinine greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST or AST &gt; 5 times ULN&#xD;
&#xD;
          -  Compromised coagulation: INR (International normalised ratio) &gt;1.5, current&#xD;
             anti-coagulation therapy or hemorrhagic disorders.&#xD;
&#xD;
          -  History of severe diseases involving heart, kidney, marrow, lung or central neural&#xD;
             system.&#xD;
&#xD;
          -  Infection diseases which need antibiotics treatment before less than 1 month.&#xD;
&#xD;
          -  Co-existing morbidity or social environment which may lead patients not to obey study&#xD;
             protocol or threat patients' safety.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liangrong Shi, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liangrong Shi, Ph.D</last_name>
    <phone>+86-13974886662</phone>
    <phone_ext>8613974886662</phone_ext>
    <email>shiliangr@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weihua Liao, M.D.</last_name>
    <phone>8613974886662</phone>
    <phone_ext>8613974886662</phone_ext>
    <email>owenliao@csu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangrong Shi, M.D.</last_name>
      <phone>8613974886662</phone>
      <email>shiliangr@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 17, 2019</study_first_submitted>
  <study_first_submitted_qc>March 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TACE</keyword>
  <keyword>Oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

